Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.

Therapeutic hypothermia beneficial for postcardiac arrest care

12 Oct 2020

Therapeutic hypothermia (TH) improves neurological outcomes for patients who had sustained cardiac arrests, reports a recent meta-analysis.

Eight randomized controlled trials (RCTs) were retrieved from online databases, corresponding to 2,026 patients who received either TH (n=1,025) or placebo (n=1,001). All studies investigated neurological outcomes as an endpoint. Pooled analysis revealed that TH led to a significantly attenuated risk (risk ratio [RR], 0.87, 95 percent confidence interval [CI], 0.77–0.98; p=0.02).

Mortality, in comparison, was assessed in seven studies, with a cumulative sample size of 1,972 patients. A total of 1,167 deaths were reported. TH had a nonsignificant protective effect against death risk relative to controls (RR, 0.94, 95 percent CI, 0.85–1.03; p=0.17).

However, in the subgroup pf patients with initial shockable rhythm, evaluated in four trials, hypothermia significantly reduced the risk of mortality (RR, 0.85, 95 percent CI, 0.73–0.99). Similarly, its efficacy against poor neurological outcomes remained significant (RR, 0.81, 95 percent CI, 0.67–0.99; p=0.04).

In contrast, TH showed no significant reduction in the risk of mortality (RR, 0.98, 95 percent CI, 0.92–1.04; p=0.50) and poor neurological outcomes (RR, 0.97, 95 percent CI, 0.92–1.01; p=0.15) in patients with initial nonshockable rhythm.

“Our meta-analysis is the largest to date including both shockable and nonshockable cardiac arrest patients. The results confirm improved neurological outcomes noted in other RCTs of TH thus further supporting the current guidelines,” the researchers said, referring to the standards of care that recommend TH for postcardiac arrest patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Oct 2020
Drinking more than two cups of coffee per day may just be the intervention that prevents hundreds of thousands of liver disease‐related deaths globally, a study reports.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Stephen Padilla, 2 days ago
Use of systemic corticosteroids does not reduce in-hospital mortality for patients with severe or critical coronavirus disease (COVID-19), which is in stark contrast to that observed in the RECOVERY clinical trial, according to a study in Wuhan, China.